Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Dose-escalation Study to Evaluate Safety, Tolerability and Immunogenicity of '2-dose Primary Series' Single Strain (Hikojima Serotype) Inactivated Oral Cholera Vaccine Formulations (Two Formulations Based on Total O1 LPS Content), in Sequential Age Descending Population of Healthy Adults and Children

NCT02823899 is registered in ClinicalTrials.gov with International Centre for Diarrhoeal Disease Research, Bangladesh as lead sponsor.

NCT NCT02823899
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02823899 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Dose-escalation Study to Evaluate Safety, Tolerability and Immunogenicity of '2-dose Primary Series' Single Strain (Hikojima Serotype) Inactivated Oral Cholera Vaccine Formulations (Two Formulations Based on Total O1 LPS Content), in Sequential Age Descending Population of Healthy Adults and Children
Lead sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2016
Completion date
November 30, 2017
Enrollment
840 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cholera